Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany)

Phytochemistry Reviews

Volumn 13, Issue 2, 2014, Pages 459-469

  Ilieva, Y ^a   Kaloyanov, K ^a   Yosifov, D ^a   Robev, B ^b   Zhelezova, I ^a   Genova, M ^c   Mihova, A ^c   Balatzenko, G ^c   Zaharieva, M M ^d   Berger, M R ^e   Konstantinov, S M ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b Specialized Hospital for Active Treatment of Oncologic Diseases   (Bulgaria)

^c National Specialized Hospital for Active Treatment of Hematological Diseases   (Bulgaria)

^d INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticlastogenic effect; Antineoplastic activity; CTCL; Curcumin; Topical treatment

Indexed keywords

AMINOPEPTIDASE; ANTINEOPLASTIC AGENT; CASPASE; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA; GLUTATHIONE; I KAPPA B; MICROSOMAL AMINOPEPTIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BULGARIA; CANCER CELL; CHROMOSOME ABERRATION; CURCUMA LONGA; CUTANEOUS T CELL LYMPHOMA; DNA FRAGMENTATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ETHNOPHARMACOLOGY; EUROPEAN UNION; GERMANY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TRADITIONAL MEDICINE;

CURCUMA LONGA;

EID: 84902368943     PISSN: 15687767     EISSN: 1572980X     Source Type: Journal    
DOI: 10.1007/s11101-014-9351-7     Document Type: Article

References (91)

1. Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39(1):41-47
2. Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41(1):40-59
3. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30(2):85-94
4. Aggarwal BB, Sethi G, Ahn KS et al (2006a) Targeting signal-transducer- and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091:151-169 (Pubitemid 47092233)
5. Aggarwal S, Ichikawa H, Takada Y et al (2006b) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69(1):195-206 (Pubitemid 43048906)
6. Alaikov T, Konstantinov SM, Tzanova T et al (2007) Antineoplastic and anticlastogenic properties of curcumin. Ann N Y Acad Sci 1095:355-370 (Pubitemid 47092467)
7. Anand P, Kunnumakkara AB, Newman RA et al (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807-818
8. Anand P, Thomas SG, Kunnumakkara AB et al (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76(11):1590-1611
9. Aoki H, Takada Y, Kondo S et al (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72(1):29-39 (Pubitemid 46998522)
10. Balasubramanian S, Eckert RL (2007) Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J Biol Chem 282(9):6707-6715 (Pubitemid 47100891)
11. Barik A, Mishra B, Shen L et al (2005) Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic Biol Med 39(6):811-822 (Pubitemid 41139894)
12. Barik A, Mishra B, Kunwar A et al (2007) Comparative study of copper(II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. Eur J Med Chem 42(4):431-439 (Pubitemid 46517793)
13. Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171(7):3863-3871 (Pubitemid 37254592)
14. Bharti AC, Shishodia S, Reuben JM et al (2004a) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175-3184 (Pubitemid 38451696)
15. Bharti AC, Takada Y, Aggarwal BB (2004b) Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172(10):5940-5947 (Pubitemid 38621193)
16. Bhattacharyya S, Mandal D, Saha B et al (2007) Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282(22):15954-15964 (Pubitemid 47100378)
17. Burg G, Kempf W, Cozzio A et al (2005) WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 32(10):647-674 (Pubitemid 41719746)
18. Cao J, Jia L, Zhou H-M et al (2006) Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol Sci 91(2):476-483 (Pubitemid 43827300)
19. Chakravarti N, Myers JN, Aggarwal BB (2006) Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 119(6):1268-1275 (Pubitemid 44258799)
20. Chen W-F, Deng S-L, Zhou B et al (2006) Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radic Biol Med 40(3):526-535 (Pubitemid 43139688)
21. Cho JW, Lee KS, Kim C (2007) Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19(3):469-474
22. Criscione VD, Weinstock MA (2007) Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 143(7):854-859 (Pubitemid 47076482)
23. Dhandapani KM, Mahesh VB, Brann DW (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102(2):522-538 (Pubitemid 47000605)
24. Duvoix A, Blasius R, Delhalle S et al (2005) Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223(2):181-190 (Pubitemid 40719616)
25. Fang J, Lu J, Holmgren A (2005) Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280(26):25284-25290 (Pubitemid 40934623)
26. Gaedeke J, Noble NA, Border WA (2005) Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int 68(5):2042-2049 (Pubitemid 43117779)
27. Ghoneim AI (2009) Effects of curcumin on ethanol-induced hepatocyte necrosis and apoptosis: implication of lipid peroxidation and cytochrome c. Naunyn Schmiedebergs Arch Pharmacol 379(1):47-60
28. Goel A, Aggarwal BB (2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62(7):919-930
29. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75(4):787-809
30. Gradisar H, Keber MM, Pristovsek P et al (2007) MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 82(4):968-974 (Pubitemid 47511057)
31. Guenova ML, Michova A, Balatzenko GN et al (2012) A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia-a possible new therapeutic target. Hematology 17(3):132-139
32. Gupta SC, Kim JH, Prasad S et al (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29(3):405-434
33. Gupta SC, Kim JH, Kannappan R et al (2011a) Role of nuclear factor j B-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med 236(6):658-671
34. Gupta SC, Prasad S, Kim JH et al (2011b) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28(12):1937-1955
35. Gupta SC, Patchva S, Koh W et al (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39(3):283-299
36. Hatcher H, Planalp R, Cho J et al (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65(11):1631-1652
37. Huang TS, Lee SC, Lin JK (1991) Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 88(12):5292-5296
38. Jagetia GC, Aggarwal BB (2007) "Spicing up" of the immune system by curcumin. J Clin Immunol 27(1):19-35
39. Jain S, Zain J, O'Connor O (2012) Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol 5:24
40. Javvadi P, Segan AT, Tuttle SW et al (2008) The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 73(5):1491-1501 (Pubitemid 351574839)
41. Jefremov V, Zilmer M, Zilmer K et al (2007) Antioxidative effects of plant polyphenols: from protection of G protein signaling to prevention of age-related pathologies. Ann N Y Acad Sci 1095:449-457 (Pubitemid 47092475)
42. Joe B, Lokesh BR (1994) Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta 1224(2):255-263
43. Kapur S, Tiemann M, Menke MA et al (2005) The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(?) lymphoproliferative diseases. Indian J Med Res 121(1):46-54 (Pubitemid 40305575)
44. Khafif A, Hurst R, Kyker K et al (2005) Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132(2):317-321 (Pubitemid 40431151)
45. Kim YH, Liu HL, Mraz-Gernhard S et al (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139(7):857-866 (Pubitemid 36898920)
46. Kim SJ, Son TG, Park HR et al (2008) Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem 283(21):14497-14505
47. Kobayashi T, Hashimoto S, Horie T (1997) Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem Pharmacol 54(7):819-824 (Pubitemid 27404683)
48. Koiram PR, Veerapur VP, Kunwar A et al (2007) Effect of curcumin and curcumin copper complex (1:1) on radiation-induced changes of anti-oxidant enzymes levels in the livers of Swiss albino mice. J Radiat Res 48(3):241-245 (Pubitemid 46884358)
49. Konstantinov SM, Kostovski A, Berger MR (2002) Will human urinary bladder carcinoma respond to treatment with alkylphosphocholines and curcumin? Facta Univ Ser Med Biol 9(1):111-113
50. Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20(10):1759-1766 (Pubitemid 44574987)
51. Kunnumakkara AB, Guha S, Krishnan S et al (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67(8):3853-3861 (Pubitemid 46762173)
52. Kunwar A, Kunwar A, Narang H et al (2007) Delayed activation of PKCdelta and NFkappaB and higher radioprotection in splenic lymphocytes by copper (II)-Curcumin (1) complex as compared to curcumin. J Cell Biochem 102(5):1214-1224 (Pubitemid 350220042)
53. Kunwar A, Barik A, Mishra B et al (2008) Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 1780(4):673-679
54. Kurup VP, Barrios CS (2008) Immunomodulatory effects of curcumin in allergy. Mol Nutr Food Res 52(9):1031-1039
55. Lamprecht B, Kreher S, Mobs M et al (2012) The tumour suppressor p53 is frequently nonfunctional in Sezary syndrome. Br J Dermatol 167(2):240-246
56. Landis-Piwowar KR, Milacic V, Chen D et al (2006) The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 9(6):263-273 (Pubitemid 46357634)
57. Lev-Ari S, Starr A, Vexler A et al (2006a) Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res 26(6B):4423-4430 (Pubitemid 46031517)
58. Lev-Ari S, Strier L, Kazanov D et al (2006b) Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 45(2):171-177 (Pubitemid 43160078)
59. Li M, Zhang Z, Hill DL et al (2007) Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67(5):1988-1996 (Pubitemid 46424215)
60. Li JY, Horwitz S, Moskowitz A et al (2012) Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 4:75-89
61. Ligeret H, Barthelemy S, Zini R et al (2004) Effects of curcumin and curcumin derivatives on mitochondrial permeability transition pore. Free Radic Biol Med 36(7):919-929 (Pubitemid 38401063)
62. Liontas A, Yeger H (2004) Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 24(2B):987-998 (Pubitemid 38625049)
63. McNally SJ, Harrison EM, Ross JA et al (2007) Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med 19(1):165-172
64. Meghana K, Sanjeev G, Ramesh B (2007) Curcumin prevents streptozotocin-induced islet damage by scavenging free radicals: a prophylactic and protective role. Eur J Pharmacol 577(1-3):183-191 (Pubitemid 47632529)
65. Mitra A, Chakrabarti J, Banerji A et al (2006) Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp2. J Environ Pathol Toxicol Oncol 25(4):679-690
66. Mukhopadhyay A, Basu N, Ghatak N et al (1982) Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12(4):508-515 (Pubitemid 13218984)
67. Padhye S, Banerjee S, Chavan D et al (2009) Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 26(11):2438-2445
68. Park C, Moon D-O, Choi I-W et al (2007) Curcumin induces apoptosis and inhibits prostaglandin E(2) production in synovial fibroblasts of patients with rheumatoid arthritis. Int J Mol Med 20(3):365-372
69. Park J, Ayyappan V, Bae E-K et al (2008) Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2(4):317-326
70. Patel BB, Sengupta R, Qazi S et al (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122(2):267-273 (Pubitemid 350234711)
71. Priyadarsini KI, Maity DK, Naik GH et al (2003) Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic Biol Med 35(5):475-484 (Pubitemid 37289157)
72. Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11(3):495-510
73. Reddy AC, Lokesh BR (1992) Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem 111(1-2):117-124
74. Selvam C, Jachak SM, Thilagavathi R et al (2005) Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett 15(7):1793-1797 (Pubitemid 40380734)
75. Shishodia S, Amin HM, Lai R et al (2005) Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70(5):700-713 (Pubitemid 41058705)
76. Shishodia S, Singh T, Chaturvedi MM (2007) Modulation of transcription factors by curcumin. Adv Exp Med Biol 595:127-148
77. Song G, Mao YB, Cai QF et al (2005) Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 38(12):1791-1798 (Pubitemid 43078608)
78. Stanchev S, Pencheva I, Konstantinov S et al (2012) Application of UV-V is spectrophotometric and chemiluminescent methods for the evaluation of the antioxidant action of curcumin. J Serb Chem Soc 77(8):1063-1069
79. Sung B, Kunnumakkara AB, Sethi G et al (2009) Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8(4):959-970
80. Suzuki M, Nakamura T, Iyoki S et al (2005) Elucidation of anti-allergic activities of curcumin-related compounds with a special reference to their anti-oxidative activities. Biol Pharm Bull 28(8):1438-1443 (Pubitemid 41379695)
81. Syng-Ai C, Kumari AL, Khar A (2004) Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 3(9):1101-1108 (Pubitemid 39295007)
82. Tourkina E, Gooz P, Oates JC et al (2004) Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol 31(1):28-35 (Pubitemid 38888036)
83. Tsvetkov P, Asher G, Reiss V et al (2005) Inhibition of NAD(P)H: quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 102(15):5535-5540 (Pubitemid 40530293)
84. Wan XH, Li YW, Luo XP (2007) Curcumin attenuated the lipid peroxidation and apoptotic liver injury in copper-overloaded rats. Zhonghua Er Ke Za Zhi 45(8):604-608
85. Wong HK, Mishra A, Hake T et al (2011) Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 155(2):150-166
86. Wu J, Wood GS (2011) Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 147(4):443-449
87. Xiao H, Xiao Q, Zhang K et al (2010) Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R. Ann Hematol 89(4):399-404
88. Yosifov DY, Todorov PT, Zaharieva MM et al (2011) Erucyl-phospho-N, N, N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother Pharmacol 67(1):13-25
89. Yosifov DY, Kaloyanov KA, Guenova ML et al (2014) Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk Res 38(1):49-56
90. Zhang C, Li B, Zhang X et al (2010) Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol 130(8):2110-2119
91. Zsila F, Bikádi Z, SimonyiM(2004) Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein. Bioorg Med Chem 12(12):3239-3245 (Pubitemid 38680713)